US FDA approves Phesgo (pertuzumab, trastuzumab and hyaluronidase) for treatment of breast cancer

Approval of Phesgo, which can be administered at home by health care professionals based on phase III RCT which met its primary endpoint, demonstrating non-inferior levels of pertuzumab in blood during a given dosing interval when compared to IV administration of pertuzumab.


US Food and Drug Administration